CRC can upregulate Nrf2, mitochondrial biogenesis, and dopamine release, while it may downregulate or inhibit Aβ and synuclein aggregation, APP gene expression, β-secretase, oxidative damage, NF-κB activation, MAPK signaling pathway, PPAR-γ, mitochondrial dysfunction, inflammation, apoptosis, and ROS. The gene discussed is APP; the disease is colorectal carcinoma.